Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Fish Oil Swims Ahead in Dietary Brain Protection Race
7 September 2004. Organism-level experimental data now lend some support to the epidemiologic evidence that the fatty acids in fish oil can protect against Alzheimer disease. Writing in Neuron, a research team led by Greg Cole and Frédéric Calon of the University of California, Los Angeles, reports that removing n-3 polyunsaturated fatty acids (PUFAs) from mouse chow leads to reductions in several significant postsynaptic cytoskeletal proteins, accompanied by learning deficits, in AD transgenic mice. The molecular and behavioral changes could be reversed by adding back the n-3 PUFA docosahexaenoic acid (DHA) to the chow.

Western society is awash in advice to eat certain foods or supplements because they contain fatty acids or antioxidants that may reduce the risk of developing AD. Although a growing body of epidemiological and in-vitro work supports many of these theoretical benefits (see ARF related news story), solid data from live critters, not to mention humans, are needed.

At the heart of the study by Calon and colleagues lies a very astute observation: The carefully crafted chow that laboratory mice eat is chock-full of those n-3 PUFAs that epidemiologic and in-vitro studies have hailed as neuroprotective. Could this help explain, ask the authors, why APP transgenic mice fail to show the deficits in synaptic markers associated with Alzheimer disease?

The authors, swinging the fatty acid content away from n-3 PUFAs, concocted a new, safflower oil-based chow. When they fed this chow to 17-month-old Tg2576 mice, they detected significant changes to levels of postsynaptic structural proteins. For example, dendritic actin levels were reduced, as evidenced by a higher ratio of fractin (a fragment of actin thought to be a caspase cleavage product) to intact actin. Supporting the notion that the postsynaptic actin cytoskeleton is perturbed in the Tg2576 mice, the researchers also found decreases in postsynaptic drebrin. Drebrin is an actin-binding protein concentrated in the brain, especially in dendritic spines, but has been found to be substantially reduced in AD (see, for example, Harigaya et al., 1996). Conversely, and in keeping with previous work, the authors found no corresponding changes in the presynaptic proteins synaptophysin or SNAP-25. Associated with these physiological changes, the learning capacity of the mice in the Morris water maze was significantly reduced.

The good news? Adding DHA to the diet rescued the behavioral deficits, as well as the alterations in postsynaptic actin and drebrin. But how might DHA in the diet have mediated these benefits? Noting that DHA has been shown to activate the neuroprotective phosphotidylinositol-3 (PI3) kinase pathway, which can work via Akt phosphorylation to block caspase activation, the authors assayed this pathway at several points. They found that the n-3 PUFA-depleted chow led to 80-90 percent reduction in one subunit of PI3-kinase, as well as reductions in Akt phosphorylation. DHA supplementation rescued both of these deficits (see ARF related news story on Akt’s involvement in preventing neuronal and muscle damage).

The PI3-kinase pathway links DHA levels to caspase activity, which mediates apoptosis through protein cleavage. Calon and colleagues found that DHA depletion impacts the wonderfully named BAD (for BCL2-antagonist of cell death), which regulates caspases. BAD can be stymied by Akt phosphorylation at BAD's serine 136, and Calon and colleagues found significantly reduced phosphorylation at this BAD residue in the mice fed a DHA-poor diet. DHA supplementation, however, boosted BAD phosphorylation.

The authors even managed to link DHA to the other pillar of nutritional links to AD—oxidative stress. They found evidence that the low n-3 PUFA diet produces more protein carbonyls, markers of oxidative protein damage, another effect that is prevented by DHA in the mouse chow. Which can bring us back to caspases and actin, as the authors propose a model whereby oxidative stress might promote caspase cleavage of actin.

The authors propose a detrimental feed-forward loop in postsynaptic membranes, at least in this mouse AD model, in which oxidative stress is instigated by Aβ and compounded by a diet low in DHA. The oxidative stress further depletes DHA, which is particularly sensitive to lipid peroxidation. An extension of this model posits that without sufficient DHA, activity in the PI3-kinase pathway drops, opening the way for BAD to promote caspase-mediated cleavage of actin. All in all, this is a pretty catastrophic scenario for the postsynaptic membrane.

In an editorial that mostly praises these findings, Lennart Mucke and Robert Pitas of the University of California, San Francisco, do ask for one more bit of work. Noting that lipid manipulations, particularly of cholesterol, impact plaque load and neuronal dystrophy, they suggest that the authors should have assessed these AD hallmarks. "If alterations of DHA in neural membranes affected the production, deposition, or clearance of Aβ, the neuronal alterations observed on the low DHA/PFA diet might represent, at least in part, an Aβ dose effect. Naturally, confirmation of such an effect would not diminish the potential therapeutic significance of the results Calon and colleagues obtained," they write.—Hakon Heimer.

Reference:
Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N Jr, Ashe KH, Frautschy SA, Cole GM. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 2004 Sep 2;43(5):633-45. Abstract

Mucke L, Pitas RE. Food for Thought; Essential Fatty Acid Protects against Neuronal Deficits in Transgenic Mouse Model of AD. Neuron. 2004 Sep 2;43(5):596-9. Abstract

 
Comments on News and Primary Papers
  Comment by:  Colin Meyer
Submitted 8 September 2004  |  Permalink Posted 8 September 2004

With regard to the recent focus upon a diet rich in fish and its protective effect against Alzheimer's disease, please allow me to point out that the assumption that this is attributable to omega-3 fatty acids may be misguided.

There are two groups of foods that provide unusually high levels of silicic acid. Thin-skinned fruits such as grapes and blueberries evaporate moisture through the epidermous, thereby concentrating the solubilized silicon within the fruit.

And over the eons silicic acid endlessly concentrates in the oceans in the same manner as salt.

Thus, the two food groups from which consumers can expect to elevate their blood levels of silicic acid are thin-skinned fruit and marine seafood. And the two foods for which epidemiological studies have indicated a protective effect against Alzheimer's disease are red wine and fish.

View all comments by Colin Meyer


  Comment by:  Mary Reid
Submitted 9 September 2004  |  Permalink Posted 10 September 2004

Does this study support a dissociation between LTP and spatial memory?

Itokazu and colleagues (1) report that DHA inhibits the induction of long-term potentiation in the CA1 area in rats, as is shown to be the case for Aβ in many studies.

I'd also be interested in the answer to the question proposed by Lennart Mucke and Robert Pitas as to whether production of Aβ is affected by DHA.

Reference:
Itokazu N, Ikegaya Y, Nishikawa M, Matsuki N. Bidirectional actions of docosahexaenoic acid on hippocampal neurotransmissions in vivo. Brain Res. 2000 Apr 17;862(1-2):211-6. Abstract

References:


View all comments by Mary Reid

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad